At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 271 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of Baricitinib in Patients With Moderate-to-Severe Plaque Psoriasis
In Brief
A Phase 2 clinical trial evaluating Placebo and Baricitinib for Psoriasis and 2 related conditions. Completed, enrolled 271 participants across 35 sites in 4 countries.
Detailed Summary
This is a dose-ranging study designed to investigate the efficacy and safety of Baricitinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index (PASI) score and routine safety assessments.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis, Skin Diseases, Skin Diseases, Papulosquamous
CountriesCanada, Japan, Puerto Rico, United States
CollaboratorsIncyte Corporation
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2011
First PostedDec 2011
Primary CompletionDec 2012
Study CompletionAug 2014
TodayJul 2026
First PostedDec 13, 2011
Enrollment StartDec 1, 2011
Primary CompletionDec 1, 2012
Study CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 14.6 years ago
Interventions
Placebodrug
Administered orally
Baricitinibdrug
Administered orally